BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company’s New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate DEXTENZA™ (dexamethasone insert) 0.4mg, for the treatment of ocular pain following ophthalmic surgery. The resubmission is intended to address manufacturing deficiencies cited by the FDA in the Agency’s July 2017 Complete Response Letter.
“We are pleased to announce the resubmission of the DEXTENZA NDA,” said Antony Mattessich, President and Chief Executive Officer. “Since last July, we have worked to make substantial improvements in our manufacturing processes and quality oversight that have allowed us to reach this important milestone. However, while the resubmission is significant, our focus remains on the end goal of making DEXTENZA available to physicians and patients. We anticipate that the DEXTENZA resubmission will be designated Class 2 (six-month review) which would imply a target action date under the Prescription Drug User Fee Act at the end of 2018.”
About DEXTENZA™
DEXTENZA is a corticosteroid
intracanalicular insert placed through the punctum, a natural opening in
the eye lid, into the canaliculus and is designed to deliver
dexamethasone to the ocular surface for up to 30 days without
preservatives. Following treatment, DEXTENZA is intended to resorb and
exit the nasolacrimal system without the need for removal. DEXTENZA has
completed Phase 3 evaluation for the treatment of ocular pain and
inflammation following ophthalmic surgery. Upon approval for pain, the
Company intends to submit an NDA supplement for the treatment of
inflammation following ocular surgery. DEXTENZA is also in Phase 3
clinical development for allergic conjunctivitis.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.
is a biopharmaceutical company focused on the formulation, development,
and commercialization of innovative therapies for diseases and
conditions of the eye using its proprietary bioresorbable hydrogel-based
formulation technology. Ocular Therapeutix has resubmitted an NDA for
post-surgical pain for its lead product candidate, DEXTENZA™
(dexamethasone insert), which has completed Phase 3 clinical development
for the treatment of ocular pain and inflammation following ophthalmic
surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development
for the reduction of intraocular pressure in patients with primary
open-angle glaucoma and ocular hypertension. The Company’s earlier stage
assets include OTX-TIC, an extended-delivery travoprost intracameral
implant for the reduction of intraocular pressure in patients with
glaucoma and ocular hypertension, as well as sustained release
intravitreal implants for the treatment of retinal diseases. These
intravitreal implants include OTX-TKI, a tyrosine kinase inhibitor
(TKI), and, in collaboration with Regeneron, OTX-IVT, an
extended-delivery protein-based anti-vascular endothelial growth factor
(VEGF) trap, both for the treatment of retinal diseases. Ocular
Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal
corneal incisions following cataract surgery.
Forward Looking Statements
Any statements in this press
release about future expectations, plans and prospects for the Company,
including the development and regulatory status of the Company’s product
candidates, such as the Company’s regulatory submissions for and the
timing and conduct of, or implications of results from, clinical trials
of DEXTENZA™ for the treatment of post-surgical ocular pain and
inflammation, including with respect to manufacturing deficiencies
identified by the FDA, the Company’s expectations regarding the NDA
filed with the FDA, the FDA’s response to the resubmitted NDA and the
prospects for approvability of DEXTENZA for these indications, OTX-TP
for the treatment of primary open-angle glaucoma and ocular hypertension,
OTX-TIC for the treatment of primary open-angle glaucoma and ocular
hypertension, OTX-TKI for the treatment of retinal diseases including
wet AMD, and OTX-IVT as an extended-delivery formulation of the VEGF
trap aflibercept for the treatment of retinal diseases including wet
AMD; the ongoing development of the Company’s extended-delivery hydrogel
depot technology; the potential utility of any of the Company’s product
candidates; potential commercialization of the Company’s product
candidates; the potential benefits and future operation of the
collaboration with Regeneron Pharmaceuticals, including any potential
future payments thereunder; the sufficiency of the Company’s cash
resources and other statements containing the words "anticipate,"
"believe," "estimate," "expect," "intend", "goal," "may", "might,"
"plan," "predict," "project," "target," "potential," "will," "would,"
"could," "should," "continue," and similar expressions, constitute
forward-looking statements within the meaning of The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors. Such forward-looking statements involve
substantial risks and uncertainties that could cause the Company’s
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or implied by
the forward-looking statements. Such risks and uncertainties include,
among others, those related to the timing and costs involved in
commercializing ReSure® Sealant or any product candidate that receives
regulatory approval, the initiation, timing and conduct of clinical
trials, availability of data from clinical trials and expectations for
regulatory submissions and approvals, the Company’s scientific approach
and general development progress, the availability or commercial
potential of the Company’s product candidates, the sufficiency of cash
resources, the outcome of the Company’s ongoing legal proceedings and
need for additional financing or other actions and other factors
discussed in the “Risk Factors” section contained in the Company’s
quarterly and annual reports on file with the Securities and Exchange
Commission. In addition, the forward-looking statements included in this
press release represent the Company’s views as of the date of this
release. The Company anticipates that subsequent events and developments
will cause the Company’s views to change. However, while the Company may
elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the date
of this release.